Network Pharmacology and Molecular Docking Integrated with Molecular Dynamics Simulations Investigate the Pharmacological Mechanism of Yinchenhao Decoction in the Treatment of Non-alcoholic Fatty Liver Disease
Authors:
- 1 August 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 21 (5) , 721-737
Abstract
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) has become a significant health and economic burden globally. Yinchenhao decoction (YCHD) is a traditional Chinese medicine formula that has been validated to exert therapeutic effects on NAFLD. Objective: The current study aimed to explore the pharmacological mechanisms of YCHD on NAFLD and further identify the potential active compounds acting on the main targets. Methods: Compounds in YCHD were screened and collected from TCMSP and published studies, and their corresponding targets were obtained from the Swisstargetprediction and SEA databases. NAFLD-related targets were searched in the GeneCards and DisGeNet databases. The “compound-intersection target” network was constructed to recognize the key compounds. Moreover, a PPI network was constructed to identify potential targets. GO and KEGG analyses were performed to enrich the functional information of the intersection targets. Then, molecular docking was used to identify the most promising compounds and targets. Finally, molecular dynamics (MD) simulations were performed to verify the binding affinity of the most potential compounds with the key targets. Results: A total of 53 compounds and 556 corresponding drug targets were collected. Moreover, 2684 NAFLD-related targets were obtained, and 201 intersection targets were identified. Biological processes, including the apoptotic process, inflammatory response, xenobiotic metabolic process, and regulation of MAP kinase activity, were closely related to the treatment of NAFLD. Metabolic pathways, non-alcoholic fatty liver disease, the MAPK signaling pathway, and the PI3K-Akt signaling pathway were found to be the key pathways. Molecular docking showed that quercetin and isorhamnetin were the potential active compounds, while AKT1, IL1B, and PPARG were the most promising targets. MD simulations further verified that the binding of PPARG-isorhamnetin (-35.96 ± 1.64 kcal/mol) and AKT1-quercetin (-31.47 ± 1.49 kcal/mol) was due to their lowest binding free energy. Conclusion: This study demonstrated that YCHD exerts therapeutic effects for the treatment of NAFLD through multiple targets and pathways, providing a theoretical basis for further pharmacological research on the potential mechanisms of YCHD in NAFLD.Keywords
Funding Information
- Shenzhen Science and Technology Planning Project (JCYJ20190812161605538)
- Shenzhen Key Laboratory (ZDSYS20210623092000002)
- Shenzhen Science and Technology Innovation Commission Project (JCYJ202205 31092014034)
- Shenzhen Traditional Chinese Medicine Hospital ‘‘3030 Program’’ Chinese Medicine Clinical Project (G3030202115)
- Guangdong Provincial Enterprise Joint Project (2022A1515220189)
- Science and Technology Development Fund, Macau SAR (0098/2021/A2, 0099/2018/A3)
This publication has 68 references indexed in Scilit:
- Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese miceCellular and Molecular Life Sciences, 2023
- Bioinformatics analysis reveals molecular connections between non-alcoholic fatty liver disease (NAFLD) and COVID-19Journal of Cell Communication and Signaling, 2022
- Ameliorative effects of Cirsium japonicum extract and main component cirsimaritin in mice model of high‐fat diet‐induced metabolic dysfunction‐associated fatty liver diseaseFood Science & Nutrition, 2021
- Antipyretic and hepatoprotective potential of Tinospora crispa and investigation of possible lead compounds through in silico approachesFood Science & Nutrition, 2019
- Molecular Dynamics Simulation of Proteins2019
- Ginsenoside Rg5 induces G2/M phase arrest, apoptosis and autophagy via regulating ROS-mediated MAPK pathways against human gastric cancerBiochemical Pharmacology, 2019
- Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver diseaseJournal of Cellular Physiology, 2019
- A Survey of Web-Based Chemogenomic Data Resources2018
- Simultaneous quantitation of 14 active components inYinchenhaodecoction by using ultra high performance liquid chromatography with diode array detection: Method development and ingredient analysis of different commonly prepared samplesJournal of Separation Science, 2016
- Chinese herbal medicine in the treatment of nonalcoholic fatty liver diseaseChinese Journal of Integrative Medicine, 2012